Few treatments in women’s health have generated as much confusion or controversy as menopausal hormone therapy (MHT).
Following the publication of the Women’s Health Initiative (WHI) in 2002, millions of women abandoned hormone therapy over fears of breast cancer and heart disease.
Today, the pendulum has swung in the opposite direction, with claims that estrogen can prevent dementia, protect the heart, and even slow aging.
Neither extreme accurately reflects the evidence.
Menopausal hormone therapy is a highly effective treatment with meaningful benefits, but it’s neither a universal anti-aging therapy nor something women should automatically fear.
What Does Menopausal Hormone Therapy Actually Do?
The benefits of hormone therapy are well established in several important areas:
- Hot Flashes and Night Sweats: Systemic estrogen remains the most effective treatment for these often-disruptive symptoms.
- Genitourinary Health: Local vaginal estrogen relieves dryness and irritation, improves certain urinary symptoms, and helps prevent recurrent urinary tract infections that often plague women as we age.
- Bone Health: Systemic MHT prevents accelerated menopausal bone loss and reduces osteoporotic fractures while treatment continues, but protection diminishes after discontinuation.
These benefits are supported by The Menopause Society’s hormone therapy guidance and the 2025 AUA guideline on genitourinary syndrome of menopause.
But there’s another benefit that deserves more attention: quality of life. A woman who wakes repeatedly with night sweats, sleeps poorly, and struggles with fatigue, irritability, and difficulty concentrating may experience improvements across all these areas when her menopausal symptoms are effectively treated.
That doesn’t necessarily mean estrogen directly improves every one of those systems. Often, it’s the downstream effect of restoring sleep and relieving symptoms that disrupt daily life. That benefit shouldn’t be underestimated.
What About the WHI and Breast Cancer?
The WHI identified genuine risks, but its findings were widely generalized beyond the women and hormone formulations actually studied.
The average participant was 63, and the principal combined-hormone regimen used oral conjugated equine estrogens and medroxyprogesterone acetate, a synthetic progestogen. That’s quite different from the transdermal estradiol and micronized progesterone frequently prescribed today.
Importantly, breast cancer outcomes also differed by regimen in the study. While combined estrogen-progestin therapy was associated with increased breast cancer incidence, estrogen alone given to women who had undergone hysterectomy and therefore didn’t require progestin therapy to protect their uterus was associated with lower breast cancer incidence and mortality in long-term follow-up.
These findings fundamentally challenge the blanket assertion that MHT increases risk of breast cancer.
Modern hormone formulations may offer important safety advantages. Transdermal estradiol, delivered through the skin rather than orally, appears to carry a lower risk of blood clots. Similarly, micronized progesterone may have a more favorable breast cancer risk profile than the synthetic progestin used in the WHI.
While these findings are encouraging, they’re based largely on observational research, and definitive long-term randomized trials are still lacking. For a thoughtful review of these controversies, see the International Menopause Society’s 2024 white paper.
Can Hormone Therapy Prevent Heart Disease or Dementia?
Here, enthusiasm may be ahead of the evidence.
Cardiovascular Health: For healthy women who begin MHT before age 60 or within 10 years of menopause, the overall benefit-risk profile is generally favorable. Starting later carries greater risks, particularly for cardiovascular events and blood clots. Transdermal estradiol appears to have a lower thrombotic risk than oral estrogen, which is one reason I generally favor it.
But MHT should not be prescribed specifically to prevent heart disease.
Cognition and Dementia: Estrogen has important effects on the brain, and researchers continue to investigate whether treatment timing influences cognitive outcomes. However, randomized trials have not established that MHT prevents Alzheimer’s disease or dementia.
Improved sleep may certainly help with concentration and mental clarity, but we’ve yet to see evidence demonstrating direct protection against cognitive decline.
Mood: Estrogen therapy may improve depressive symptoms in some women during perimenopause, although evidence is less convincing after menopause.
Longevity: Despite increasingly popular claims, MHT has not been proven to reverse biological aging or extend lifespan.
Timing Matters, but Age Isn’t Everything
Current recommendations generally favor initiating systemic MHT before age 60 or within 10 years of menopause, when the benefit-risk balance is most favorable.
But these aren’t absolute cutoffs. Turning 60 doesn’t suddenly make hormone therapy dangerous, and women don’t automatically need to discontinue treatment at 65.
For someone who started therapy near menopause, continues to benefit, and has no significant emerging risk factors, ongoing treatment may be entirely reasonable.
Starting treatment for the first time later in life requires more caution. A 2026 update from The Menopause Society reinforces the importance of individualized assessment rather than rigid age-based rules.
So, Is Menopausal Hormone Therapy Right for You?
That depends on your symptoms, age, medical history, personal risk factors, and what you hope to gain from treatment.
Women with certain conditions, including a history of breast cancer, blood clots, stroke, or significant cardiovascular or liver disease, may not be appropriate candidates for systemic therapy. Unexplained vaginal bleeding also requires evaluation before treatment.
Importantly, low-dose vaginal estrogen has a different safety profile from systemic menopausal hormone therapy and may be appropriate even when systemic treatment isn’t recommended.
For most women, extensive hormone testing isn’t necessary. Treatment decisions are generally guided by symptoms, menstrual history, overall health, and response to therapy, not by chasing a particular estrogen level.
At Personal Health MD, we take the time to understand how menopause affects each woman’s life, carefully assess the potential benefits and risks of menopausal hormone therapy, and develop an individualized plan.
The goal isn’t simply to prescribe hormones. It’s to help women feel better, stay healthy, and make informed decisions about their care.
Ready to Talk About Hormone Therapy?
To schedule an appointment or learn more, call (617) 585-1500 or visit our website.
